Journal Article
. 2019 Dec;382(7).
doi: 10.1056/NEJMoa1914609.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Rashmi K Murthy 1 Sherene Loi 1 Alicia Okines 1 Elisavet Paplomata 1 Erika Hamilton 1 Sara A Hurvitz 1 Nancy U Lin 1 Virginia Borges 1 Vandana Abramson 1 Carey Anders 1 Philippe L Bedard 1 Mafalda Oliveira 1 Erik Jakobsen 1 Thomas Bachelot 1 Shlomit S Shachar 1 Volkmar Müller 1 Sofia Braga 1 Francois P Duhoux 1 Richard Greil 1 David Cameron 1 Lisa A Carey 1 Giuseppe Curigliano 1 Karen Gelmon 1 Gabriel Hortobagyi 1 Ian Krop 1 Sibylle Loibl 1 Mark Pegram 1 Dennis Slamon 1 M Corinna Palanca-Wessels 1 Luke Walker 1 Wentao Feng 1 Eric P Winer 1 
Affiliations
  • PMID: 31825569
  •     51 citations

Abstract

Background: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase.

Methods: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety.

Results: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group.

Conclusions: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).

2019 San Antonio Breast Cancer Symposium: San Antonio, TX, USA, 10-14 December 2019.
Martin Chopra.
Target Oncol, 2020 Jan 26; 15(1). PMID: 31980995
Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance.
Seiichiro Mitani, Hisato Kawakami.
Cancers (Basel), 2020 Feb 14; 12(2). PMID: 32050652    Free PMC article.
Review.
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond.
Ricardo L B Costa, Brian J Czerniecki.
NPJ Breast Cancer, 2020 Mar 21; 6. PMID: 32195333    Free PMC article.
Review.
Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2020 Mar 27; 8(1). PMID: 32210163    Free PMC article.
Review.
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Diana Lüftner, Andreas Schneeweiss, +16 authors, Michael P Lux.
Geburtshilfe Frauenheilkd, 2020 Apr 24; 80(4). PMID: 32322108    Free PMC article.
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, +46 authors, Maurizio Scaltriti.
Cancer Discov, 2020 Mar 28; 10(5). PMID: 32213539    Free PMC article.
The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies.
Jordyn Kreutzfeldt, Brett Rozeboom, Nandini Dey, Pradip De.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368385    Free PMC article.
Review.
Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019.
Isabell Witzel, Matteo Lambertini, +2 authors, Volkmar Müller.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398990    Free PMC article.
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.
Alexandra S Zimmer, Seth M Steinberg, +11 authors, Patricia S Steeg.
Future Oncol, 2020 Apr 10; 16(14). PMID: 32270710    Free PMC article.
Circulating Tumor DNA Biomarkers for Early Detection of Oligometastasis.
David M Routman, Bhishamjit S Chera, Gaorav P Gupta.
Cancer J, 2020 Mar 25; 26(2). PMID: 32205535    Free PMC article.
Evolving treatment strategies of brain metastases from breast cancer: current status and future direction.
Jae Sik Kim, In Ah Kim.
Ther Adv Med Oncol, 2020 Jul 09; 12. PMID: 32636942    Free PMC article.
Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience.
Ding Ren, Hao Cheng, +6 authors, Hong Zhao.
Ther Adv Med Oncol, 2020 Jul 14; 12. PMID: 32655700    Free PMC article.
Review.
New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?pi.
Essia Mezni, Cécile Vicier, +3 authors, Anthony Gonçalves.
Cancers (Basel), 2020 Jun 18; 12(6). PMID: 32545895    Free PMC article.
Review.
Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care.
Joanne E Mortimer, Laura Kruper, +10 authors, Yuan Yuan.
J Clin Med, 2020 Jul 01; 9(6). PMID: 32599960    Free PMC article.
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Nancy U Lin, Virginia Borges, +26 authors, Eric P Winer.
J Clin Oncol, 2020 May 30; 38(23). PMID: 32468955    Free PMC article.
Landscape of combination therapy trials in breast cancer brain metastasis.
Jawad Fares, Deepak Kanojia, +2 authors, Maciej S Lesniak.
Int J Cancer, 2020 Feb 23; 147(7). PMID: 32086955    Free PMC article.
Proliferative Classification of Intracranially Injected HER2-positive Breast Cancer Cell Lines.
Yuka Kuroiwa, Jun Nakayama, +3 authors, Kentaro Semba.
Cancers (Basel), 2020 Jul 10; 12(7). PMID: 32640677    Free PMC article.
ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications.
Wook Jin.
J Clin Med, 2020 Jul 28; 9(7). PMID: 32708604    Free PMC article.
Review.
Heterogeneity and vascular permeability of breast cancer brain metastases.
Maria V Babak, Michael R Zalutsky, Irina V Balyasnikova.
Cancer Lett, 2020 Jun 21; 489. PMID: 32561415    Free PMC article.
Novel targeted therapies for metastatic breast cancer.
Khalid Jazieh, Ruth Bell, Nayan Agarwal, Jame Abraham.
Ann Transl Med, 2020 Aug 15; 8(14). PMID: 32793751    Free PMC article.
Review.
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study.
Eva Blondeaux, Arlindo R Ferreira, +14 authors, Lucia Del Mastro.
ESMO Open, 2020 Aug 21; 5(4). PMID: 32817059    Free PMC article.
Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer From the US and Chinese Perspectives.
Qiuji Wu, Weiting Liao, +3 authors, Qiu Li.
Front Oncol, 2020 Aug 28; 10. PMID: 32850425    Free PMC article.
The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer.
Aena Patel, Nisha Unni, Yan Peng.
Cancers (Basel), 2020 Aug 01; 12(8). PMID: 32731409    Free PMC article.
Review.
Subtype switching in breast cancer brain metastases: a multicenter analysis.
Alexander F C Hulsbergen, An Claes, +8 authors, Marike L D Broekman.
Neuro Oncol, 2020 Jan 24; 22(8). PMID: 31970416    Free PMC article.
Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance.
Alex J Gooding, William P Schiemann.
Mol Cancer Res, 2020 Jun 07; 18(9). PMID: 32503922    Free PMC article.
Review.
Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition.
Bryan Ngo, Eugenie Kim, +37 authors, Michael E Pacold.
Cancer Discov, 2020 Jun 24; 10(9). PMID: 32571778    Free PMC article.
The Role of Stereotactic Biopsy in Brain Metastases.
Kenny K H Yu, Ankur R Patel, Nelson S Moss.
Neurosurg Clin N Am, 2020 Sep 15; 31(4). PMID: 32921348    Free PMC article.
Review.
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Cristina Saura, Mafalda Oliveira, +33 authors, NALA Investigators.
J Clin Oncol, 2020 Jul 18; 38(27). PMID: 32678716    Free PMC article.
Molecular and cellular mechanisms underlying brain metastasis of breast cancer.
Mari Hosonaga, Hideyuki Saya, Yoshimi Arima.
Cancer Metastasis Rev, 2020 May 14; 39(3). PMID: 32399646    Free PMC article.
Review.
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, +42 authors, E P Winer.
Ann Oncol, 2020 Sep 27; 31(12). PMID: 32979513    Free PMC article.
A view on the landscape of breast cancer brain metastases.
Rachna Malani.
CNS Oncol, 2020 Sep 30; 9(3). PMID: 32990026    Free PMC article.
Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment.
Arthur Foulon, Pierrick Theret, Lise Rodat-Despoix, Philippe Kischel.
Cancers (Basel), 2020 Sep 20; 12(9). PMID: 32947780    Free PMC article.
Review.
HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line.
Hye Jin Lee, Seungho Shin, +4 authors, Kyong Hwa Park.
Cancers (Basel), 2020 Sep 19; 12(9). PMID: 32942617    Free PMC article.
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
Liling Huang, Shiyu Jiang, Yuankai Shi.
J Hematol Oncol, 2020 Oct 29; 13(1). PMID: 33109256    Free PMC article.
Review.
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab.
Laura L Michel, Andreas D Hartkopf, +27 authors, Tanja N Fehm.
Cancers (Basel), 2020 Oct 22; 12(10). PMID: 33080911    Free PMC article.
Receptor discordance in breast cancer brain metastases: when knowledge is power.
Sarah Sammons, Amanda E D Van Swearingen, Carey K Anders.
Neuro Oncol, 2020 Jun 02; 22(8). PMID: 32479604    Free PMC article.
Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Simon Peter Gampenrieder, Vanessa Castagnaviz, Gabriel Rinnerthaler, Richard Greil.
Cancer Manag Res, 2020 Nov 06; 12. PMID: 33149670    Free PMC article.
Review.
Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer.
Xue Yang, Dapeng Wu, Shengli Yuan.
Technol Cancer Res Treat, 2020 Oct 10; 19. PMID: 33034269    Free PMC article.
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.
Paul W Sperduto, Shane Mesko, +36 authors, Minesh P Mehta.
J Clin Oncol, 2020 Sep 16; 38(32). PMID: 32931399    Free PMC article.
Update Breast Cancer 2020 Part 4 - Advanced Breast Cancer.
Hans Tesch, Volkmar Müller, +16 authors, Wolfgang Janni.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173239    Free PMC article.
Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine.
Elena Laakmann, Julius Emons, +27 authors, Andreas D Hartkopf.
Geburtshilfe Frauenheilkd, 2020 Nov 12; 80(11). PMID: 33173241    Free PMC article.
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.
Hanna Huebner, Christian M Kurbacher, +23 authors, Johannes Ettl.
BMC Cancer, 2020 Nov 13; 20(1). PMID: 33176725    Free PMC article.
Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
James Crespo, Hongxia Sun, +6 authors, Bora Lim.
PLoS One, 2020 Nov 13; 15(11). PMID: 33180796    Free PMC article.
Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity.
Ali Alsalme, T Pooventhiran, +3 authors, Renjith Thomas.
J Mol Model, 2020 Nov 18; 26(12). PMID: 33200284    Free PMC article.
Resistance and Overcoming Resistance in Breast Cancer.
Andrea Luque-Bolivar, Erika Pérez-Mora, Victoria Eugenia Villegas, Milena Rondón-Lagos.
Breast Cancer (Dove Med Press), 2020 Nov 19; 12. PMID: 33204149    Free PMC article.
Review.
Lapatinib Plus Local Radiation Therapy for Brain Metastases From HER-2 Positive Breast Cancer Patients and Role of Trastuzumab: A Systematic Review and Meta-Analysis.
Muhammad Khan, Zhihong Zhao, +2 authors, Guixiang Liao.
Front Oncol, 2020 Nov 27; 10. PMID: 33240815    Free PMC article.
Systematic Review.
Brain Metastasis in Breast Cancer Patients-Need for Improvement.
Isabell Witzel, Leticia Oliveira-Ferrer, Volkmar Müller.
Cancers (Basel), 2020 Nov 05; 12(11). PMID: 33142993    Free PMC article.
Therapeutic Strategies for the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive (HR+/HER2+) Breast Cancer: A Review of the Current Literature.
Eirini Thanopoulou, Leila Khader, +5 authors, Valentina Guarneri.
Cancers (Basel), 2020 Nov 14; 12(11). PMID: 33182657    Free PMC article.
Review.
Management of Brain and Leptomeningeal Metastases from Breast Cancer.
Alessia Pellerino, Valeria Internò, +3 authors, Roberta Rudà.
Int J Mol Sci, 2020 Nov 18; 21(22). PMID: 33198331    Free PMC article.
Review.
HER2 splice variants in breast cancer: investigating their impact on diagnosis and treatment outcomes.
Vic Hart, Hannah Gautrey, John Kirby, Alison Tyson-Capper.
Oncotarget, 2020 Nov 28; 11(46). PMID: 33245725    Free PMC article.
Review.
Prevention, Detection, and Management of Heart Failure in Patients Treated for Breast Cancer.
Agneta Månsson Broberg, Jürgen Geisler, +8 authors, Geeta Gulati.
Curr Heart Fail Rep, 2020 Sep 27; 17(6). PMID: 32979150    Free PMC article.
Review.